Logo image of IPHA

INNATE PHARMA SA-SPONS ADR (IPHA) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:IPHA - US45781K2042 - ADR

1.753 USD
-0.06 (-3.15%)
Last: 1/14/2026, 8:00:03 PM
Fundamental Rating

2

Taking everything into account, IPHA scores 2 out of 10 in our fundamental rating. IPHA was compared to 528 industry peers in the Biotechnology industry. IPHA has a bad profitability rating. Also its financial health evaluation is rather negative. IPHA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • IPHA had negative earnings in the past year.
  • In the past year IPHA has reported a negative cash flow from operations.
  • In the past 5 years IPHA always reported negative net income.
  • In the past 5 years IPHA always reported negative operating cash flow.
IPHA Yearly Net Income VS EBIT VS OCF VS FCFIPHA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M -60M

1.2 Ratios

  • The Return On Assets of IPHA (-49.55%) is comparable to the rest of the industry.
  • IPHA's Return On Equity of -895.24% is on the low side compared to the rest of the industry. IPHA is outperformed by 78.60% of its industry peers.
Industry RankSector Rank
ROA -49.55%
ROE -895.24%
ROIC N/A
ROA(3y)-25.61%
ROA(5y)-23.47%
ROE(3y)-227.3%
ROE(5y)-154.41%
ROIC(3y)N/A
ROIC(5y)N/A
IPHA Yearly ROA, ROE, ROICIPHA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400 -500

1.3 Margins

  • The Gross Margin of IPHA (49.52%) is better than 75.38% of its industry peers.
  • In the last couple of years the Gross Margin of IPHA has declined.
  • The Profit Margin and Operating Margin are not available for IPHA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 49.52%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.49%
GM growth 5Y-4.49%
IPHA Yearly Profit, Operating, Gross MarginsIPHA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

2

2. Health

2.1 Basic Checks

  • IPHA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • IPHA has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, IPHA has more shares outstanding
  • IPHA has a worse debt/assets ratio than last year.
IPHA Yearly Shares OutstandingIPHA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
IPHA Yearly Total Debt VS Total AssetsIPHA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

  • IPHA has an Altman-Z score of -6.45. This is a bad value and indicates that IPHA is not financially healthy and even has some risk of bankruptcy.
  • IPHA has a worse Altman-Z score (-6.45) than 64.77% of its industry peers.
  • IPHA has a Debt/Equity ratio of 11.55. This is a high value indicating a heavy dependency on external financing.
  • The Debt to Equity ratio of IPHA (11.55) is worse than 81.06% of its industry peers.
Industry RankSector Rank
Debt/Equity 11.55
Debt/FCF N/A
Altman-Z -6.45
ROIC/WACCN/A
WACC6.64%
IPHA Yearly LT Debt VS Equity VS FCFIPHA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M 200M

2.3 Liquidity

  • A Current Ratio of 2.21 indicates that IPHA has no problem at all paying its short term obligations.
  • IPHA has a Current ratio of 2.21. This is in the lower half of the industry: IPHA underperforms 73.48% of its industry peers.
  • A Quick Ratio of 2.21 indicates that IPHA has no problem at all paying its short term obligations.
  • IPHA's Quick ratio of 2.21 is on the low side compared to the rest of the industry. IPHA is outperformed by 71.40% of its industry peers.
Industry RankSector Rank
Current Ratio 2.21
Quick Ratio 2.21
IPHA Yearly Current Assets VS Current LiabilitesIPHA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

3

3. Growth

3.1 Past

  • IPHA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -30.42%.
  • IPHA shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -75.86%.
  • Measured over the past years, IPHA shows a very negative growth in Revenue. The Revenue has been decreasing by -28.80% on average per year.
EPS 1Y (TTM)-30.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.82%
Revenue 1Y (TTM)-75.86%
Revenue growth 3Y1.38%
Revenue growth 5Y-28.8%
Sales Q2Q%-79.85%

3.2 Future

  • The Earnings Per Share is expected to decrease by -3.32% on average over the next years.
  • The Revenue is expected to grow by 38.93% on average over the next years. This is a very strong growth
EPS Next Y-32.84%
EPS Next 2Y-10.27%
EPS Next 3Y-3.32%
EPS Next 5YN/A
Revenue Next Year-26.21%
Revenue Next 2Y3.05%
Revenue Next 3Y2.41%
Revenue Next 5Y38.93%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
IPHA Yearly Revenue VS EstimatesIPHA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 100M 200M 300M 400M
IPHA Yearly EPS VS EstimatesIPHA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -0.2 -0.4 -0.6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • IPHA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IPHA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IPHA Price Earnings VS Forward Price EarningsIPHA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IPHA Per share dataIPHA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4

4.3 Compensation for Growth

  • A cheap valuation may be justified as IPHA's earnings are expected to decrease with -3.32% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-10.27%
EPS Next 3Y-3.32%

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for IPHA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

INNATE PHARMA SA-SPONS ADR

NASDAQ:IPHA (1/14/2026, 8:00:03 PM)

1.753

-0.06 (-3.15%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13
Earnings (Next)03-26
Inst Owners9.46%
Inst Owner Change-1.48%
Ins Owners0.92%
Ins Owner ChangeN/A
Market Cap161.57M
Revenue(TTM)6.00M
Net Income(TTM)-46.05M
Analysts80
Price Target5.7 (225.16%)
Short Float %0.37%
Short Ratio0.99
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.34%
PT rev (3m)-6.86%
EPS NQ rev (1m)0.07%
EPS NQ rev (3m)0%
EPS NY rev (1m)0.07%
EPS NY rev (3m)-230.42%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-18.95%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 23.11
P/FCF N/A
P/OCF N/A
P/B 26.96
P/tB 26.96
EV/EBITDA N/A
EPS(TTM)-0.6
EYN/A
EPS(NY)-0.55
Fwd EYN/A
FCF(TTM)-0.52
FCFYN/A
OCF(TTM)-0.52
OCFYN/A
SpS0.08
BVpS0.07
TBVpS0.07
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -49.55%
ROE -895.24%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 49.52%
FCFM N/A
ROA(3y)-25.61%
ROA(5y)-23.47%
ROE(3y)-227.3%
ROE(5y)-154.41%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.49%
GM growth 5Y-4.49%
F-Score1
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 11.55
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 10.84%
Cap/Sales 2.82%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.21
Quick Ratio 2.21
Altman-Z -6.45
F-Score1
WACC6.64%
ROIC/WACCN/A
Cap/Depr(3y)22.77%
Cap/Depr(5y)23.45%
Cap/Sales(3y)3.3%
Cap/Sales(5y)8.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-30.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.82%
EPS Next Y-32.84%
EPS Next 2Y-10.27%
EPS Next 3Y-3.32%
EPS Next 5YN/A
Revenue 1Y (TTM)-75.86%
Revenue growth 3Y1.38%
Revenue growth 5Y-28.8%
Sales Q2Q%-79.85%
Revenue Next Year-26.21%
Revenue Next 2Y3.05%
Revenue Next 3Y2.41%
Revenue Next 5Y38.93%
EBIT growth 1Y-31.37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year68.86%
EBIT Next 3Y68.81%
EBIT Next 5YN/A
FCF growth 1Y-27.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-31.01%
OCF growth 3YN/A
OCF growth 5YN/A

INNATE PHARMA SA-SPONS ADR / IPHA FAQ

What is the ChartMill fundamental rating of INNATE PHARMA SA-SPONS ADR (IPHA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to IPHA.


Can you provide the valuation status for INNATE PHARMA SA-SPONS ADR?

ChartMill assigns a valuation rating of 0 / 10 to INNATE PHARMA SA-SPONS ADR (IPHA). This can be considered as Overvalued.


What is the profitability of IPHA stock?

INNATE PHARMA SA-SPONS ADR (IPHA) has a profitability rating of 1 / 10.


What is the financial health of INNATE PHARMA SA-SPONS ADR (IPHA) stock?

The financial health rating of INNATE PHARMA SA-SPONS ADR (IPHA) is 2 / 10.